Review Lentiviral Vectors and Antiretroviral Intrinsic Immunity

ABSTRACTMulticellular organisms have evolved under relentless attacks from pathogens, and as a consequence havespiked their genomes with numerous genes that serve to thwart these threats, notably through the buildingof the innate and adaptive arms of the immune system. The innate immune system is by far the most ancient,being found as widely as in plants and Drosophila , while adaptive immunity arose with the emergence of car-tilaginous fishes. Innate immunity enters rapidly into the game during the course of an infection and gener-ally involves the recognition by specific cellular receptors of common pathogen-associated patterns to elicitbroad defensive responses, mediated in humans by interferons, macrophages, and natural killer cells, amongstothers. When innate immunity fails to eradicate the infection quickly, adaptive immune responses enter intoplay, to generate exquisitely specific defenses to virtually any pathogen, thanks to a quasi-infinite repertoireof nonself receptors and effectors. A specific form of innate immunity, coined “intrinsic immunity,” completesthis protection by providing a constant, always-on, line of defense, generally through intracellular obstaclesto the replication of pathogens. This component of the immune system has gained much attention as it wasdiscovered that it is a cornerstone of the resistance of mammals against retroviruses. One of these newly dis-covered intracellular molecular weapons, the APOBEC family of proteins, is active against several classes ofretroelements. We present here the current state of knowledge on this rapidly evolving field and discuss im-plications for gene therapy.

[1]  B. Cullen,et al.  Differential Sensitivity of Murine Leukemia Virus to APOBEC3-Mediated Inhibition Is Governed by Virion Exclusion , 2005, Journal of Virology.

[2]  M. Löchelt,et al.  The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  W. Greene,et al.  Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells , 2005, Nature.

[4]  B. Cullen,et al.  Inhibition of a Yeast LTR Retrotransposon by Human APOBEC3 Cytidine Deaminases , 2005, Current Biology.

[5]  T. Heidmann,et al.  APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses , 2005, Nature.

[6]  R. König,et al.  APOBEC3B and APOBEC3C Are Potent Inhibitors of Simian Immunodeficiency Virus Replication* , 2004, Journal of Biological Chemistry.

[7]  R. Blasco,et al.  Susceptibility of different leukocyte cell types to Vaccinia virus infection , 2004, Virology Journal.

[8]  D. Trono,et al.  The Innate Antiretroviral Factor APOBEC3G Does Not Affect Human LINE-1 Retrotransposition in a Cell Culture Assay* , 2004, Journal of Biological Chemistry.

[9]  M. Scharff,et al.  The role of activation-induced cytidine deaminase in antibody diversification, immunodeficiency, and B-cell malignancies. , 2004, The Journal of allergy and clinical immunology.

[10]  V. Pathak,et al.  Human Apolipoprotein B mRNA-editing Enzyme-catalytic Polypeptide-like 3G (APOBEC3G) Is Incorporated into HIV-1 Virions through Interactions with Viral and Nonviral RNAs* , 2004, Journal of Biological Chemistry.

[11]  Jianzhi Zhang,et al.  Rapid evolution of primate antiviral enzyme APOBEC3G. , 2004, Human molecular genetics.

[12]  W. Brown,et al.  APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo , 2004, Current Biology.

[13]  L. Kleiman,et al.  The Interaction between HIV-1 Gag and APOBEC3G* , 2004, Journal of Biological Chemistry.

[14]  A. Takaori-Kondo,et al.  APOBEC3G Targets Specific Virus Species , 2004, Journal of Virology.

[15]  M. Malim,et al.  APOBEC-Mediated Editing of Viral RNA , 2004, Science.

[16]  M. Emerman,et al.  Ancient Adaptive Evolution of the Primate Antiviral DNA-Editing Enzyme APOBEC3G , 2004, PLoS biology.

[17]  Matthew J. Stephens,et al.  Global effect of PEG-IFN-α and ribavirin on gene expression in PBMC in vitro , 2004 .

[18]  Boro Dropulic,et al.  Antisense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance , 2004, Journal of Virology.

[19]  B. Cullen,et al.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV‐1 and HIV‐2 Vif proteins , 2004, The EMBO journal.

[20]  Richard Carroll,et al.  Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Takeshi Kurosu,et al.  Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication , 2004, Journal of Virology.

[22]  D. Trono,et al.  A Single Amino Acid Determinant Governs the Species-specific Sensitivity of APOBEC3G to Vif Action* , 2004, Journal of Biological Chemistry.

[23]  Markus G. Manz,et al.  Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.

[24]  D. Trono,et al.  Inhibition of Hepatitis B Virus Replication by APOBEC3G , 2004, Science.

[25]  N. Landau,et al.  A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Cullen,et al.  A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Yunkai Yu,et al.  Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex , 2003, Science.

[28]  M. Malim,et al.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif , 2003, Nature Medicine.

[29]  S. Fan,et al.  Molecular therapeutics of HBV. , 2003, Current gene therapy.

[30]  R. König,et al.  Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif , 2003, Cell.

[31]  Hui Zhang,et al.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.

[32]  Gersende Caron,et al.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.

[33]  M. Malim,et al.  DNA Deamination Mediates Innate Immunity to Retroviral Infection , 2003, Cell.

[34]  Reuben S Harris,et al.  Immunity through DNA deamination. , 2003, Trends in biochemical sciences.

[35]  F. Clavel,et al.  Hypermutation of HIV-1 DNA in the Absence of the Vif Protein , 2003, Science.

[36]  F. Alt,et al.  Transcription-targeted DNA deamination by the AID antibody diversification enzyme , 2003, Nature.

[37]  J. Wedekind,et al.  Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. , 2003, Trends in genetics : TIG.

[38]  D. Trono,et al.  Modalities of Interleukin-7-Induced Human Immunodeficiency Virus Permissiveness in Quiescent T Lymphocytes , 2002, Journal of Virology.

[39]  M. Malim,et al.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.

[40]  I. Dunham,et al.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. , 2002, Genomics.

[41]  T. Waters,et al.  Thymine-DNA glycosylase and G to A transition mutations at CpG sites. , 2000, Mutation research.

[42]  M. Shapiro,et al.  Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.

[43]  M. Malim,et al.  Evidence for a newly discovered cellular anti-HIV-1 phenotype , 1998, Nature Medicine.

[44]  Navid Madani,et al.  An Endogenous Inhibitor of Human Immunodeficiency Virus in Human Lymphocytes Is Overcome by the Viral Vif Protein , 1998, Journal of Virology.

[45]  Y. Korin,et al.  Progression to the G1b Phase of the Cell Cycle Is Required for Completion of Human Immunodeficiency Virus Type 1 Reverse Transcription in T Cells , 1998, Journal of Virology.

[46]  J. Taylor,et al.  Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Trono,et al.  Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells , 1993, Journal of virology.

[48]  J. Sodroski,et al.  Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes , 1992, Journal of virology.

[49]  P. Tiollais,et al.  Hepatitis B virus. , 1991, Scientific American.

[50]  Jerome A. Zack,et al.  HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.

[51]  J. Stoye,et al.  Retrotransposons, Endogenous Retroviruses, and the Evolution of Retroelements , 1997 .